The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: A systematic review and meta-analysis

Keyphrases

• Linagliptin 100%
• Type 2 Diabetes Mellitus (T2DM) 100%
• Glycemic Control 100%
• Tolerability 100%
• Meta-analysis 100%
• Systematic Meta-analysis 100%
• Type 2 Diabetic Patients 100%
• Hemoglobin A1c (HbA1c) 50%
• Placebo 50%
• Fasting Plasma Glucose 37%
• Metformin 37%
• Pioglitazone 25%
• Upper Respiratory Tract Infection 25%
• Adverse Events 25%
• Monotherapy 25%
• Disposition Index 25%
• Sulfonylurea 25%
• Back Pain 12%
• Dipeptidyl peptidase-4 (DPP-4) 12%
• Hypoglycemia 12%
• Randomized Clinical Trial 12%
• Multiple Databases 12%
• Placebo Groups 12%
• Insulin Secretion 12%
• Weight Reduction 12%
• Durability of Response 12%
• Hypertension 12%
• Reduction Strategies 12%
• Active Agent 12%
• Fluid Retention 12%
• Insulin Sensitivity 12%
• Headache Pain 12%
• Nausea 12%
• Cost-effectiveness 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Tolerability 100%
• Linagliptin 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Placebo 62%
• Hemoglobin A1c 50%
• Metformin 37%
• Pioglitazone 25%
• Sulfonylurea 25%
• Upper Respiratory Tract Infection 25%
• Monotherapy 25%
• Adverse Event 25%
• Dipeptidyl Peptidase IV Inhibitor 12%
• Randomized Clinical Trial 12%
• Hypoglycemia 12%
• Biological Marker 12%
• Headache 12%
• Backache 12%
• Nausea 12%